The stock market as a whole showed a significant adjustment in the stock market, with higher valuation levels in the pharmaceutical sector and CXO (R&D and production outsourcing services) and other subsectors in CXO (R&D and production outsourcing services), medical services, etc., in the pharmaceutical sector, released a report. Financially, the Bank believes that the industry-wide fund's allocation to the pharmaceutical sector has fallen to a very low level; from the valuation level of core companies, it has fallen to mid-to-low levels in almost three years, and valuation attractiveness is becoming apparent.
The Bank noted that despite the short-term impact of the pandemic, the parent company continued to maintain strong growth through strong business management capabilities, and actively undertook anti-epidemic responsibilities during the pandemic, and further increased its social reputation; recommended active attention to El-Eye (300015.SZ), Haigia Medical (06078.HK), General CURATIVE MEDICINE (600763.SH), ETC. As for the CXO (R&D and Production Outsourcing) segment, which is currently in the process of adjusting its valuation, the CCP believes that the 2022 to 2023 order situation expected to be disclosed in the 2021 report and the planned expansion of capacity in 2022 will be stronger catalysts. The situation will be more positive, indicating that CXO is still a good misfit for 2022 Positioned assets, the configuration opportunities for the core of the block after a rollback are worth paying attention to.
CHINA APPENDS HONG KONG SHARES GOOD PHARMACEUTICALS (02269.HK), SINDA BIO (01801.HK), CONNOA-B (02162.HK), KANGFANG BIO-B (09926.HK), RONG CHANG BIO-B (09995.HK), HAIGIA MEDICAL AND TIME ANGEL (06699.HK).